Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Feature|Articles|September 30, 2025
- Vol.26/No.11
- Volume 26
- Issue 11
Real-World Evidence Complements and Contextualizes Randomized Clinical Trial Insights in Colorectal Cancer
Author(s)Ashley Chan
Fact checked by: Chris Ryan
Although clinical trials are considered a “gold standard” in identifying the efficacy of treatments, real-world data help address unmet needs in colorectal cancer.
Advertisement
Advertisement
As data from prospective clinical trials continue to drive change and bring newer treatments to the colorectal cancer (CRC) realm, real-world evidence has helped further address unmet needs for patients who may be ineligible for clinical trials or descend from underrepresented populations.
Related to this article
Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.
The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Anktiva plus BCG improved efficacy vs BCG alone in cohort A of QUILT-2.005 in BCG-naive NMIBC.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Advertisement
Advertisement